Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-06-24 16:22:49 ET · period of report 2026-06-22 · accession 0001610717-26-000293 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-06-24 16:22 | 2026-06-22 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $34.44 | -30.0K | 1.11M | -3% | -$1.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-06-22 | S | D | 8,527 | $33.29 | 1,129,853 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Class A Common Stock | 2026-06-22 | S | D | 9,991 | $34.28 | 1,119,862 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2026-06-22 | S | D | 9,821 | $35.32 | 1,110,041 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2026-06-22 | S | D | 1,661 | $36.16 | 1,108,380 | D | — | — | (F1) The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. (F5) This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |